August was a month in which the S&P 500 largely drifted sideways, but there was a good deal going on in the various sectors that make up the index. The graphic below shows sector performance for...
The accompanying table presents a global index of healthcare companies which have received FDA approval for innovative products in the last 12 months. The index excludes all approvals for label...
According to IMS Health (NYSE: RX), global sales of cancer drugs will grow at a compounded annual rate of 12-15%, nearing $80 billion by 2012. Improved diagnosis and equipment, as well as...
. . . And so the summer doldrums continue, with the market still finding no clear direction. Small-cap value maintained its leadership role last week with a 0.9% gain, and small caps, in general,...
Cytori Therapeutics (NSDQ: CYTX) (click on name or image below for my PDF stock profile) entered into a binding letter of intent to complete a StemSource Cell Bank sales agreement with Astrea...
Clarient (NSDQ: CLRT) provides value-added, lab-based diagnostic services in the detection, monitoring, and treatment of cancer by performing highly specialized oncology molecular testing to improve...
Spectranetics (NSDQ: SPNC) is a rapidly growing cardiovascular medical device company with a profitable razor/razor blade business model that also includes a service component. The Company develops,...
We're well past the halfway point of the year, and things are already looking different as far as exchange traded funds (ETFs) go. For one, oil has been heading south for most of July. In fact, it...
Further to my Biotech on a Tear post earlier this week, today’s action confirms that biotechnology stocks are officially breaking out. The chart below is a weekly chart of IBB, the most active of...
Shares of ImClone Systems (NSDQ: IMCL) are skyrocketing in pre-market action, trading up over 40% to around $66 per share on word of a $60 per share all-cash buyout offer by Bristol-Myers...
